Product Description

Recombinant 2019-nCoV NSP8 is produced by our E.coli expression system and the target gene encoding Ala1-Gln198 is expressed with a 6His tag at the C-terminus.

Background:Cleavage by the viral main protease, 3CLpro results in generating the nsp8 protein, The nsp8 protein has been shown to associate with several other nsps and to colocalize with these nsps in cytoplasmic complexes that are important for viral RNA synthesis. It forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, may synthesize substantially longer products than oligonucleotide primers. Nsp8 was shown to have RNA-dependent RNA polymerase (RdRp) activity that could be involved in producing primers utilized by nsp12 which is normally accepted to be the RdRp for SARS-CoV.Formulation:Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 10% Glycerol, pH 8.5.Purity:> 95 % as determined by reducing SDS-PAGE.Endotoxin:< 1.0 EU per µg as determined by the LAL method.Shipping:This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at<-20°C. Avoid freeze-thaw cycles.

More Details:Sequence:Ala1-Gln198Fusion Tag:C-6HisAccession:YP_009725304.1Species:VirusExpression System:E. coliMol Mass:25 kDaAP Mol Mass:25 kDaSynonyms:SARS-CoV 2 nsp8Datasheet

FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES.Manufactured by: Elabscience

"iwaichem公司成立于1947年，主要在日本东京生产和销售高纯试剂，超过60年的经营历史，zui近在生命科学领域销售有大的增长，特别是在诸如分子生物学，基因工程及免疫学。
我们和国内外450家生物技术公司有合作关系，并有70人的销售团队，2500多家研究机构和制药公司客户，iwaichem在日本有1.6亿美金的销售额。"